Healthcare Private Placement and M&A Transactions Review Week Ending August 21 2022

Bluejay Therapeutics: The company raised $41 million of Series B venture funding in a deal led by Arkin Bio-Ventures on August 16, 2022, putting the company’s pre-money valuation at $65 million. Yonjin Venture, Synergenics, InnoPinnacle International, Octagon Capital Advisors and RiverVest Venture Partners also participated in the round. The company is a developer of a therapeutic treatment designed to cure chronic hepatitis B virus (HBV) infection.

Moximed: The company raised $40 million of Series C venture funding through a combination of debt and equity in a deal led by Advent Life Sciences. New Enterprise Associates, Australia Future Fund, Vertex Healthcare, Gilde Healthcare, GBS Venture Partners, and Morgenthaler Ventures also participated in the round. The company is a developer of unicompartmental load absorber implants intended to improve the standard of care for patients with osteoarthritis.

Arine: The company raised $29 million of Series B venture funding from 111 West Capital and other undisclosed investors on August 17, 2022, putting the company’s pre-money valuation at $110 million. The company is a developer of a medication management platform designed to improve health and quality of life.

KeyCare: The company raised $ 24 million of Series A venture funding led by 8VC with participation of LRVHealth , Bold Capital Venture and Spectrum Health Ventures on August 17, 2022. The company is a developer of a virtual-first care platform designed to improve access to health systems.

Motivo: The company raised $14 million of Series A venture funding in a deal led by Cox Enterprises on August 18, 2022. Great Oaks Venture Capital and SteelSky Ventures also participated in the round. The company is a developer of virtual clinical supervision software designed to connect aspiring mental health professionals seeking licensure with clinical supervisors through live, HIPAA-compliant video.

Taiga Biotechnologies: The company raised $14 million of venture funding in the form of convertible debt from undisclosed investors on August 16, 2022. Taiga Biotechnologies is a clinical-stage company focused on harnessing the immune system to fight infectious disease and cancer.

Tembo Health: The company raised $8.9 million of Series 3 venture funding from Singularity Capital on August 15, 2022, putting the company’s pre-money valuation at $30 million. The company partners with senior care communities and leading clinicians to provide residents with high quality complex care through telemedicine.

Dr. B: The company raised $8 million of venture funding from Lerer Hippeau Ventures and Founders Fund on August 16, 2022. The company is a developer of a telehealth platform designed for online patients to get and fill the everyday prescriptions they depend on at the best price.

---

Turning Point Therapeutics / Bristol-Myers Squibb: The company was acquired by Bristol-Myers Squibb for $4.1 billion on August 17, 2022. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis.

Affinivax / GlaxoSmithKline: The company was acquired by GlaxoSmithKline for $3.3 billion on August 16, 2022. Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines, using its patented biotin-rhizavidin binding approach to optimize the body’s protective immune response to address infectious and other immune-mediated diseases.

GenDx / Eurobio Scientific: The company reached a definitive agreement to be acquired by Eurobio Scientific for $135 million on August 17, 2022. The company is a provider of molecular diagnostics tools intended for solid organ and stem cell transplantation.

Vici Health Sciences / Psycheceutical Bioscience: The company was acquired by Psycheceutical Bioscience for $10.5 million on August 16, 2022. The company is a developer and manufacturer of generic and branded prescription drug products intended for the US markets.

HBT Labs / American Regent: The company was acquired by American Regent for an undisclosed amount on August 17, 2022. The company provides complex injectable products and manufacturing capabilities focused on high-barrier, parenteral generic drugs with complex chemistry and manufacturing processes targeted to treatment indications including cancer and CNS disorders.

InnAVasc / W. L. Gore and Associates: The company was acquired by W. L. Gore and Associates for an undisclosed amount on August 17, 2022. The company is a manufacturer of medical devices created to offer vascular access for hemodialysis.

MHRx / Alitam Group: The company was acquired by Alitam Group for an undisclosed amount on August 19, 2022. The company is a provider of pharmacy, clinic and educational and training services based in Isleworth, United Kingdom.

Obsidio / Boston Scientific: The company was acquired by Boston Scientific for an undisclosed amount on August 15, 2022. The company provides technologies for minimally invasive image-guided procedures using innovative biomaterials.